medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2015, Número 616

<< Anterior Siguiente >>

Rev Med Cos Cen 2015; 72 (616)


Uso de drogas antihipertensivas en embarazo y postparto

González CJP, Arguelles AAB, Vargas AC

Idioma: Español
Referencias bibliográficas: 15
Paginas: 521-525
Archivo PDF: 201.83 Kb.


RESUMEN

El uso de antihipertensivos en el embarazo ha ido en aumento, debido a una mayor incidencia de obesidad, embarazos tardíos y de diabetes. Debido a la alta morbimortalidad que esta representa, se requieren de más estudios, no solamente para definir metas clínicas de PA, sino también su seguridad y posibles secuelas neonatales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bellomo, G., Venanzi, S., Saronio, P., & Verdura, C. (2011). Prognostic significance of serum uric acid in women with gestacional hypertension. Hypertension , 58: 704-708.

  2. Bramham, K., Nelson-Piercy, C., & Cgappell, L. (2014). Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ , 348:g2301.

  3. Bramham, K., Nelson-Piercy, C., Brown, M., & Chappell, L. (2013). Postpartum management of hypertension. BMJ , 346:f894.

  4. Cooper, W., Hernandez, S., Arbogast, P., & Dudley, J. (2006). Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med , 354: 2443-51.

  5. Gabbe, S., Niebyl, J., Simpson, J., Landon, M., & Galan, H. (2012). Obstetrics Normal and problem pregnancies 6th edition. Philadelphia: Elsevier.

  6. Heida, K., Zeeman, G., & Van Veen, T. (2012). Neonatal side effects of maternal labetalol treatment in severe preeclampsia. Early Human Development , 503-507.

  7. Molvi, S., Mir, S., Rana, V., Jabeen, F., & Malik, R. (2012). Role of antihypertensive therapy in mild to moderate pregnancyinduced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet , 285: 1553- 1562.

  8. Nakhai-Pou, H., Rey, E., & Berard, A. (2009). Discontinuation of antihypertensive drug use during the first trimester of pregnancy and the risk of. Am J Obstet Gynecol , 201:180.e1-8.

  9. Orbach, H., Matok, I., & Gorodischer, R. (2013). Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol , 208:301.e1-6.

  10. Peacock, W., Hilleman, D., Levy, P., Rhoney, D., & Varon, J. (2012). A systematic review of nicardipine vs labetalol for the management of hypertensive crises. The American Journal of Emergency Medicine , 30: 981-993.

  11. Podymow, T., & August, P. (2008). Update on the use of antihypertensive drugs in pregnancy. American Heart Association-Hypertension , 51: 960- 969.

  12. Sibai, B. (2012). Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol , 470-475.

  13. Xie, R., Guo, Y., Krewski, D., & Mattison, D. (2014). Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. European Journal of Obstetrics and Gynecology and Reproductive Biology , 124-128.

  14. Xie, R., Guo, Y., Krewski, D., & Mattison, D. (2013). Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. European Journal of Obstetrics & Gynecology and Reproductive Biology , 281-285.

  15. Yakoob, M., Bateman, B., Ho, E., Hernandez, S., Franklin, J., & Goodman, J. (2013). The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension , 62: 375-381.




2020     |     www.medigraphic.com